Recent Updates
Recently added Catalysts
RDY Positive Sentiment Score: 60/100

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.c

Tuesday, February 25, 2025 1 min read
Key Takeaway: Dr. Reddy's Laboratories has received the Establishment Inspection Report from the US Food & Drug Administration for its API manufacturing facility in Bollaram, Hyderabad. The inspection was classified as Voluntary Action Indicated (VAI), and the status has been concluded as 'closed' under regulatory standards. This development highlights the company's compliance with FDA regulations and supports its operational integrity.

Market Sentiment Analysis

POSITIVE FACTORS

  • The inspection by USFDA has been classified as Voluntary Action Indicated (VAI).
  • The inspection concluded as 'closed', signaling a resolution.
  • Receiving the Establishment Inspection Report indicates compliance efforts.

Full Press Release Details

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Further to our intimation dated November 19, 2024,
on the inspection conducted by the United States Food & Drug Administration (USFDA) at our API manufacturing facility (CTO-2) in Bollaram,
Hyderabad, we wish to inform you that the Company has received the Establishment Inspection Report (EIR). The USFDA has classified the
inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is "closed" under 21 CFR 20.64(d)(3).
This is for your information and record.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer & Head-CSR

Frequently Asked Questions

What stock exchanges list Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories is listed on NSE, BSE, NYSE, and NSE IFSC.

What was the result of the USFDA inspection?

The USFDA inspection resulted in a VAI classification and is now closed.

When was the USFDA inspection reported?

The inspection was reported on November 19, 2024.

Where is the API manufacturing facility located?

The API manufacturing facility is in Bollaram, Hyderabad.

Tags: RDY Viatris Investor Conferences Healthcare Dr. Reddy's USFDA inspection report API manufacturing Bollaram
Last updated: Feb 25, 2025